DJIA 16,461.32 -153.49 -0.92%
NASDAQ 4,382.85 -36.63 -0.83%
S&P 500 1,927.11 -14.17 -0.73%
market minute promo

TESARO (NASDAQ: TSRO)

26.08 -0.32 (-1.21%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TSRO $26.08 -1.21%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $26.39
Previous Close $26.40
Daily Range $25.97 - $27.10
52-Week Range $22.15 - $41.25
Market Cap $940.0M
P/E Ratio -14.67
Dividend (Yield) $0.00 (0.0%)
Volume 291,537
Average Daily Volume 407,098
Current FY EPS -$4.71

Sector

Healthcare

Industry

Drugs

TESARO (TSRO) Description

TESARO Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. Website: http://www.tesarobio.com/

News & Commentary

What Was Behind Tesaro Inc.'s 21% Pop?

Tesaro and Opko's rolapitant successfully achieved primary and secondary endpoints in reducing chemotherapy-induced nausea and vomiting.

Benzinga's Top Initiations

Weakness Seen in Tesaro, Inc. (TSRO): Stock Tumbles 9.0% - Tale of the Tape

TESARO Announces Offering of $165 Million of Convertible Senior Notes Due 2021

TRACON Pharmaceuticals Completes $27M Financing And Expands Management Team And Board of Directors

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Ap

Sector Update: Health Care Stocks End Mixed; Opko Health, Tesaro Climb After Submitting New Drug Application for Anti-Nausea Medication

Sector Update: Health Care

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

TESARO Announces Submission Of Rolapitant New Drug Application To FDA

TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog

TESARO's' (TSRO) CEO Lonnie Moulder on Q2 2014 Results - Earnings Call Transcript

See More TSRO News...